Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib in CML-CP Resistant/Intolerant to 2nd-Gen TKIs
NCT05311943Phase 3Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olverembatinib in chronic myeloid leukemia (CML), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Major Molecular Response at 12 months. Status: unknown.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05311943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311943.